In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on Moderna (MRNA – Research Report), with a price target of $32.00. The company’s shares closed yesterday ...

In a report released yesterday, Brent Thill from Jefferies maintained a Hold rating on GoDaddy (GDDY – Research Report), with a price target of ...

The S&P 500 lost 4.6%, and the Nasdaq Composite lost 10.4%. Following the trend, shares of Moderna (NASDAQ: MRNA) slid 31.8% in the first three months of the year. More recently, the conspicuous ...

Taking to Instagram, Lin shared the designs with Hamilton fans, explaining that he was tasked with the tricky challenge of ...

In a video shared to TikTok, Emily showed her step-by-step process for creating her Longhorns logo concept. Beginning with ...

Moderna has said it will open a new R&D and manufacturing facility in the UK which could lead to improved access by NHS patients to mRNA-based vaccines and drug treatments. The facility is the ...

The trial compared Moderna's MRNA-4157/V940 vaccine given alongside Merck & Co's cancer immunotherapy Keytruda (pembrolizumab) to Keytruda alone in patients with the skin cancer melanoma.

Genc and colleagues show developmental increases in neurite density and reductions in soma radius with in vivo MRI data. Combined with ex vivo gene expression data, this supports the model of ...

Copyright © 2025 MarketWatch, Inc. All rights reserved.

The biggest stories of the day delivered to your inbox.